Abstract: A JAK inhibitor may be used in preparation of a medicament. The medicament may be used for preventing and/or treating a disease or condition associated with an antitumor agent in a subject. A pharmaceutical composition may include the JAK inhibitor as may a kit. The JAK inhibitor may include a compound of formula (I) or a pharmaceutically acceptable salt thereof: Q, X, Y, and Z being independently N or C, and R1, R2 and R3 being independently a 5-6-membered aromatic ring, 5-6-membered heteroaromatic ring, 5-6-membered cycloalkyl, 5-6-membered heterocycloalkyl, amino, or amido, the aromatic ring, heteroaromatic ring, cycloalkyl, and/or heterocycloalkyl being optionally substituted by a substituent.

Abstract: The present application relates to a thymidine derivative, or use of a uridine derivative in combination with a thymidine derivative in preparation of a drug for preventing or treating a disease or disorder associated with administration of a chemotherapeutical drug in a subject. The present application further provides a method of preventing or treating a disease or disorder associated with administration of a chemotherapeutical drug in a subject comprising administering a prophylactically or therapeutically effective amount of a thymidine derivative or uridine and thymidine derivatives to a subject in need thereof.

Abstract: The present application relates to use of a nitric oxide releasing agent in the preparation of a medicament for preventing or treating diseases or disorders associated with administration of a VEGFR inhibitor and/or VEGF inhibitor. The present application further provides a method for preventing or treating diseases or disorders associated with administration of a VEGFR inhibitor and/or VEGF inhibitor in a subject. The method comprise administering, to a subject in need, a prophylactically or therapeutically effective amount of the nitric oxide releasing agent.

Abstract: The present application provides a use of a nitric oxide releasing agent in preparing a medicament, wherein the medicament is used for preventing or treating EGFR inhibition associated epithelial diseases in a subject. The present application further provides a pharmaceutical composition or a kit comprising EGFR inhibitor and nitric oxide releasing agent.